Korea FilingsFull brief — $39

DAEWON PHARMACEUTICAL CO.,LTD

대원제약(주) · KOSPI: 003220 · Pharmaceuticals and medicinal chemicals

Key facts

Korean name
대원제약(주)
Market / ticker
KOSPI · 003220
Industry
Pharmaceuticals and medicinal chemicals
Established
1961-08-09
Fiscal year ends
December
Website
www.daewonpharm.com
DART corp code
00111999
Latest revenue
₩605.4B (FY2025)

Items worth checking

low
Conversion / warrant / exchange rights exercised — shares outstanding change — filed on 2 separate dates in the last 12 months, latest 2026-02-24.

Financial summary

KRWFY2023FY2024FY2025
Revenue₩527.0B₩598.2B₩605.4B
Operating income₩32.2B₩28.2B₩3.5B
Net income₩23.5B₩9.0B−₩4.0B
Total assets₩508.0B₩583.4B₩613.7B
Total liabilities₩243.7B₩298.8B₩339.1B
Total equity₩264.3B₩284.6B₩274.6B
Share capital₩11.1B₩11.2B₩11.2B

Consolidated statements · FY2025 operating margin 0.6% · liabilities to equity 123% · Annual report FY2025 (Korean original)

Auditor opinions

PeriodAuditorOpinion
Term 65 (current)예지회계법인Unqualified
Term 64 (prior)삼정회계법인Unqualified
Term 63 (two years prior)삼정회계법인Unqualified

Largest shareholder history

No change history reported in the latest annual report.

Recent filings

DateFilingOriginal
2026-09-15Investor relations event (notice)DART
2026-08-28Fair trade compliance program status (notice)DART
2026-08-07Half-year report (2026.06)DART
2026-06-12Investor relations event (notice)DART
2026-06-10Officer / major shareholder ownership reportDART
2026-06-01Corporate governance reportDART
2026-05-15Quarterly report (2026.03)DART
2026-03-26Annual general meeting resultsDART
2026-03-26Independent director appointment / dismissal / resignationDART
2026-03-18Annual report (2025.12)DART
2026-03-18Audit report submittedDART
2026-03-13Officer / major shareholder ownership reportDART
2026-03-11Amended: Notice of shareholders meetingDART
2026-03-11Amended: Resolution to convene shareholders meetingDART
2026-02-27Fair trade compliance program status (notice)DART
2026-02-25Notice of shareholders meetingDART
2026-02-24Adjustment of conversion / exercise / exchange price (notice)DART
2026-02-20Resolution to convene shareholders meetingDART
2026-02-20Cash / in-kind dividend decisionDART
2026-02-03Revenue or profit structure changed materiallyDART

Showing the 20 most recent of 29 filings. The full brief lists all of them.

Full brief on DAEWON PHARMACEUTICAL CO.,LTD — $39 Get the full brief

For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).

Other Korean companies in Pharmaceuticals and medicinal chemicals

Data generated 2026-09-16 from OpenDART.

This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.